Antihyperglycemic agent therapy for adult patients with type 2 diabetes mellitus 2017: a position statement of the Korean Diabetes Association
Seung-Hyun Ko, Kyu Yeon Hur, Sang Youl Rhee, Nan-Hee Kim, Min Kyong Moon, Seok-O Park, Byung-Wan Lee, Hyun Jin Kim, Kyung Mook Choi, Jin Hwa Kim,
Korean J Intern Med. 2017;32(6):947-958. Published online 2017 Oct 23 DOI: https://doi.org/10.3904/kjim.2017.298
Citations to this article as recorded by 
Glomerular filtration rate as a kidney outcome of diabetic kidney disease: a focus on new antidiabetic drugs
Hyo Jin Kim, Sang Soo Kim, Sang Heon Song
The Korean Journal of Internal Medicine.2022; 37(3): 502. CrossRef
3D-QSAR-based pharmacophore determination and design of novel DPP-4 inhibitors
Sanja Rogić, Žarko Gagić
Scripta Medica.2022; 53(4): 271. CrossRef
Increasing Individual Target Glucose Levels to Prevent Hypoglycemia in Patients with Diabetes
Juyoung Shin, Hyunah Kim, Hun-Sung Kim, Churlmin Kim, Whan-Seok Choi
Korean Journal of Family Medicine.2021; 42(4): 269. CrossRef
Associations Between Preoperative Glucose and Hemoglobin A1c Level and Myocardial Injury After Noncardiac Surgery
Jungchan Park, Ah Ran Oh, Seung‐Hwa Lee, Jong‐Hwan Lee, Jeong Jin Min, Ji‐Hye Kwon, Jihoon Kim, Kwangmo Yang, Jin‐Ho Choi, Sang‐Chol Lee, Hyeon‐Cheol Gwon, Kyunga Kim, Joonghyun Ahn, Sangmin Maria Lee
Journal of the American Heart Association.2021;[Epub] CrossRef
Long-term effectiveness and safety of quadruple combination therapy with empagliflozin versus dapagliflozin in patients with type 2 diabetes: 3-year prospective observational study
Eu Jeong Ku, Dong-Hwa Lee, Hyun Jeong Jeon, Tae Keun Oh
Diabetes Research and Clinical Practice.2021; 182: 109123. CrossRef
Management of type 2 diabetes using non‐insulin glucose‐lowering therapies: a critical appraisal of clinical practice guidelines with the AGREE II instrument
W. M. J. Lam, R. Al‐Khalifah, I. D. Florez, L. Cruz‐Lopes, M. F. Sekercioglu, R. Couban, R. Fu, D. Z. I. Cherney, N. Sekercioglu
Diabetic Medicine.2020; 37(4): 636. CrossRef
Adverse Drug Events Observed with the Novel Sodium/Glucose Co-Transporter 2 Inhibitor Ipragliflozin for the Treatment of Patients with Type 2 Diabetes Mellitus: A Systematic Review and Meta-analysis of Randomized Studies
Dan Liu, Hao Chen, Fang Song, Mohamad Anis Ahmed, Hongyan Wu
Advances in Therapy.2020; 37(10): 4356. CrossRef
Validity of the Good Practice Guidelines: The example of type 2 diabetes
Benoit V. Tudrej, Delphine Favard, Hélène Vaillant-Roussel, Denis Pouchain, Nemat Jaafari, Rémy Boussageon
Diabetes Research and Clinical Practice.2020; 169: 108459. CrossRef
Effect of sodium‐glucose cotransporter 2 inhibitor, empagliflozin, and α‐glucosidase inhibitor, voglibose, on hepatic steatosis in an animal model of type 2 diabetes
Ji‐Won Kim, Ye‐Jee Lee, Young‐Hye You, Min Kyong Moon, Kun‐Ho Yoon, Yu‐Bae Ahn, Seung‐Hyun Ko
Journal of Cellular Biochemistry.2019; 120(5): 8534. CrossRef
Past and Current Status of Adult Type 2 Diabetes Mellitus Management in Korea: A National Health Insurance Service Database Analysis
Seung-Hyun Ko, Kyungdo Han, Yong-ho Lee, Junghyun Noh, Cheol-Young Park, Dae-Jung Kim, Chang Hee Jung, Ki-Up Lee, Kyung-Soo Ko
Diabetes & Metabolism Journal.2018; 42(2): 93. CrossRef